Clinical trial · Observational
A Study of Optical Imaging With Light From Radiotracers in Cancer Patients
A Feasibility Study of Non-Invasive Cerenkov Luminescence Imaging in Patients With Cancer
NCT03484884CI-TRIAL-00109623active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cerenkov luminescence imaging. | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Thyroid cancer/nodal metastasis
- description
- Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area.
- interventionNames
- Diagnostic Test: Cerenkov luminescence imaging.
Primary outcomes (1)
- measure
- Feasibility of clinical Cerenkov luminescence imaging by achieving satisfactory imaging at least a rate of 80%
- timeFrame
- Through study completion, an average of 24 hours
- description
- The primary objective is to explore the overall feasibility of clinical Cerenkov imaging on patients with any tumors with nodal metastases (existing or suspected) scheduled for routine clinical FDG PET or 131I therapy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participant is 18 years of age or old * Participant must meet one of the following: * Patients with thyroid cancer scheduled for thyroid ablation therapy with 131I * Patients with any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region who are scheduled to receive a clinical FDG PET/CT scan * Patients with metastatic prostate cancer who are schedule for Xofigo therapy with 223Ra * Patients scheduled to receive a standard of care 66Ga-DOTA-TATE or \[18f\]-PARPi PET scan in the Nuclear Medicine Clinic * Patient undergoing Lu-DOTA TATE treatment in the Nuclear Medicine Clinic Exclusion Criteria: * Patients imaged for Cerenkov luminescence are going to be required to be in a darkened enclosure for at least 10 minutes and sit still during image acquisition. Any conditions that would prevent this will exclude the patients. This includes patients who unable to sit in a dark environment, have claustrophobic, inability to sit still for a few minutes * Any other past medical, physiological or demographic concerns. This includes any patients with skin blemishes that are present at the dermis over the tumor, as these are of particular interest for use of this technique. This also includes open wounds on the area of interest.
References
Publications (1)
- DERIVEDPratt EC, Skubal M, Mc Larney B, Causa-Andrieu P, Das S, Sawan P, Araji A, Riedl C, Vyas K, Tuch D, Grimm J. Prospective testing of clinical Cerenkov luminescence imaging against standard-of-care nuclear imaging for tumour location. Nat Biomed Eng. 2022 May;6(5):559-568. doi: 10.1038/s41551-022-00876-4. Epub 2022 Apr 11. PMID 35411113